摘要

Erlotinib (Tarceva) is an oral epidermal growth factor receptor-tyrosine kinase inhibitor that is mainly used for patients with advanced or metastatic non-small-cell lung cancer. Tyrosine kinase signaling cascades also play a critical role in the pathogenesis of allergic airway inflammation and airway remodeling. However, cholinergic effects caused by erlotinib on tracheal smooth muscle remain unclear. The objective of this study was to determine the effects of erlotinib on the isolated rat tracheal smooth muscle invitro. To examine the cholinergic effects of erlotinib, invitro rat tracheal smooth muscle wasused to assess alterations in methacholine-induced contraction (served as a parasympathetic mimetic) and electrically induced contraction. The results demonstrated that the addition of erlotinib (from 1×10-8M to 1×10-4M) induced no significant effects on tracheal tension after methacholine treatment. Furthermore, erlotinib did not affect electrical field stimulation-induced spike contraction. This study demonstrated that erlotinib had no cholinergic effects invitro, suggesting it may be safe for asthmatic patients with non-small-cell lung cancer after further investigation.
原文英語
頁(從 - 到)98-101
頁數4
期刊Journal of Experimental and Clinical Medicine(Taiwan)
6
發行號3
DOIs
出版狀態已發佈 - 2014

指紋

Cholinergic Agents
Smooth Muscle
Methacholine Chloride
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Airway Remodeling
Erlotinib Hydrochloride
Epidermal Growth Factor Receptor
Electric Stimulation
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

引用此文

@article{00413482568f443483fd8b9b4668718f,
title = "Erlotinib: Lacking of cholinergic effects on tracheal smooth muscle",
abstract = "Erlotinib (Tarceva) is an oral epidermal growth factor receptor-tyrosine kinase inhibitor that is mainly used for patients with advanced or metastatic non-small-cell lung cancer. Tyrosine kinase signaling cascades also play a critical role in the pathogenesis of allergic airway inflammation and airway remodeling. However, cholinergic effects caused by erlotinib on tracheal smooth muscle remain unclear. The objective of this study was to determine the effects of erlotinib on the isolated rat tracheal smooth muscle invitro. To examine the cholinergic effects of erlotinib, invitro rat tracheal smooth muscle wasused to assess alterations in methacholine-induced contraction (served as a parasympathetic mimetic) and electrically induced contraction. The results demonstrated that the addition of erlotinib (from 1×10-8M to 1×10-4M) induced no significant effects on tracheal tension after methacholine treatment. Furthermore, erlotinib did not affect electrical field stimulation-induced spike contraction. This study demonstrated that erlotinib had no cholinergic effects invitro, suggesting it may be safe for asthmatic patients with non-small-cell lung cancer after further investigation.",
keywords = "Cholinergic effect, Electrical field stimulation, Erlotinib, Tracheal smooth muscle",
author = "Chang, {Chih Cheng} and Chuang, {Hsiao Chi} and Chun-Nin Lee and Hung, {Wen Yueh} and Wang, {Hsing Won}",
year = "2014",
doi = "10.1016/j.jecm.2014.03.007",
language = "English",
volume = "6",
pages = "98--101",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Erlotinib

T2 - Lacking of cholinergic effects on tracheal smooth muscle

AU - Chang, Chih Cheng

AU - Chuang, Hsiao Chi

AU - Lee, Chun-Nin

AU - Hung, Wen Yueh

AU - Wang, Hsing Won

PY - 2014

Y1 - 2014

N2 - Erlotinib (Tarceva) is an oral epidermal growth factor receptor-tyrosine kinase inhibitor that is mainly used for patients with advanced or metastatic non-small-cell lung cancer. Tyrosine kinase signaling cascades also play a critical role in the pathogenesis of allergic airway inflammation and airway remodeling. However, cholinergic effects caused by erlotinib on tracheal smooth muscle remain unclear. The objective of this study was to determine the effects of erlotinib on the isolated rat tracheal smooth muscle invitro. To examine the cholinergic effects of erlotinib, invitro rat tracheal smooth muscle wasused to assess alterations in methacholine-induced contraction (served as a parasympathetic mimetic) and electrically induced contraction. The results demonstrated that the addition of erlotinib (from 1×10-8M to 1×10-4M) induced no significant effects on tracheal tension after methacholine treatment. Furthermore, erlotinib did not affect electrical field stimulation-induced spike contraction. This study demonstrated that erlotinib had no cholinergic effects invitro, suggesting it may be safe for asthmatic patients with non-small-cell lung cancer after further investigation.

AB - Erlotinib (Tarceva) is an oral epidermal growth factor receptor-tyrosine kinase inhibitor that is mainly used for patients with advanced or metastatic non-small-cell lung cancer. Tyrosine kinase signaling cascades also play a critical role in the pathogenesis of allergic airway inflammation and airway remodeling. However, cholinergic effects caused by erlotinib on tracheal smooth muscle remain unclear. The objective of this study was to determine the effects of erlotinib on the isolated rat tracheal smooth muscle invitro. To examine the cholinergic effects of erlotinib, invitro rat tracheal smooth muscle wasused to assess alterations in methacholine-induced contraction (served as a parasympathetic mimetic) and electrically induced contraction. The results demonstrated that the addition of erlotinib (from 1×10-8M to 1×10-4M) induced no significant effects on tracheal tension after methacholine treatment. Furthermore, erlotinib did not affect electrical field stimulation-induced spike contraction. This study demonstrated that erlotinib had no cholinergic effects invitro, suggesting it may be safe for asthmatic patients with non-small-cell lung cancer after further investigation.

KW - Cholinergic effect

KW - Electrical field stimulation

KW - Erlotinib

KW - Tracheal smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=84901674529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901674529&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2014.03.007

DO - 10.1016/j.jecm.2014.03.007

M3 - Article

AN - SCOPUS:84901674529

VL - 6

SP - 98

EP - 101

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -